You have the chance to do a PhD at the interface of the hottest research fields in biomedicine: immunotherapy, genetic engineering and metabolism.
As a member of the Schober Lab (www.schoberlab.de
), you will investigate human antigen-specific T cell responses. A specific focus will lie on analysing the metabolism of T cells genetically engineered to express a transgenic T cell receptor via CRISPR/Cas9-mediated orthotopic TCR replacement. You will apply state-of-the-art-methods such as single-cell RNA sequencing and cutting-edge metabolomics to profile the response of engineered T cells to their cognate antigen.
For further information also see Schober, Voit et al. Nat Biomed Eng 2019,Schober, Müller et al. Nat Immunol 2020
and Fischer…Schober Nat Comm 2021
- Infectious diseases
- Antigen-specific T cell responses
- Genotype - phenotype
- Genetic engineering
- Flow cytometry
- Single-cell RNA sequencing
We are looking for a talented and highly motivated PhD student with a Master of Science degree in immunology, biology, biochemistry, biotechnology, molecular medicine, bioinformatics or equivalent. Any experience with single-cell RNA seq and/or genetic engineering (CRISPR/Cas9) and/or metabolomics would be great, but is not a requirement.
Additionally beneficial are:
- Excellent M.Sc. degree
- Good working knowledge in immunology and molecular biology
- Scientific enthusiasm
- Proficiency in English
- Ability to work in an ambitious team in a collaborative manner
- Intended pay grade depending on qualifications and personal
requirements according to TV-L (E13)
- The position is temporary
- The position is part-time (65 %)
- The earliest possible starting date is 01.02.2022
- The deadline for application is 31.12.2021
- Notes for applicants (f/m/d)
- A secure, interesting job in a motivated, open-minded team
- Careful and qualified training and support for the new challenge
- A varied and responsible field of activity with individual development
- Comprehensive health promotion offers
- All benefits of the public service incl. supplementary pension plan of the
Versorgungsanstalt des Bundes und der Länder (VBL) (Federal and State
Government Employees' Retirement Fund)
- Family-friendly environment and, where appropriate, places in a dormitory
- Crediting of work experience possible
The Friedrich-Alexander-University (FAU) Erlangen-Nürnberg has been ranked as the 2nd
most innovative university in Europe in a 2019 Reuters ranking. The significance of FAU as a center for immunology research in Germany is exemplified by the fact that FAU is consistently placed among the top three universities with regards to raising funding from the German Research Foundation (DFG) in the medicine research field "Microbiology, Virology and Immunology". Immunological research in Erlangen is bundled in the Medical Immunology Campus Erlangen (MICE), with over 100 members from FAU, medicinal departments of the university hospital or the Max Planck Institute for the science of light. The newly founded German Center for Immunotherapy (DZI) stresses the translational angle of immunological research at FAU.
Within this strong immunological and translational environment, the Schober lab is situated at the Institute of Clinical Microbiology, Immunology and Hygiene (led by Christian Bogdan), which has a strong focus on infectious diseases. The long-standing research expertise in infections is complemented by the microbiological diagnostics department at the institute and the department for clinical infectiology, which is a DGI-certified Center for Infectiology since 2005.
The Schober lab
aims at understanding and engineering human T cell immunity. Natural immunity has co-evolved with pathogens for millions of years, and the adoptive transfer of T cells represents an exciting new field of medicine for the treatment of infectious diseases and cancer. We investigate the composition and evolution of antigen-specific T cell responses over space and time. For that, we use state-of-the-art T cell receptor (TCR) sequence analyses combined with flow cytometry and single-cell transcriptomics as well as bioinformatic analyses in collaboration with machine-learning experts. With that knowledge at hand, we employ advanced genetic engineering tools such as CRISPR/Cas9 to engineer T cells in a highly precise fashion. In analogy to the field of bionics, physiological T cells for us represent a blueprint for functional and safe engineered therapeutic T cell products. We therefore follow the vision to generate physiological Advanced Genetically Engineered T cells (AGEnTs), and thereby combine the therapeutic efficacy and safety profile of physiological T cells with the versatility of cell engineering to develop therapies for patients with infectious diseases and cancer.
Dr. Kilian Schober
Tel. +49 9131 85-22571
If you are interested, please send your application (with a CV, letter of motivation and letters or names of references) toKilian.Schober@uk-erlangen.de